Patients with advanced head and neck squamous cell carcinoma receiving chemotherapy have a poor prognosis partly due to normal tissue toxicity; therefore, development of a tumor-targeted drug delivery platform to minimize collateral toxicity is a goal of cancer nanomedicine. Aptamers can achieve this purpose. While conventional Systematic Evolution of Ligands by Exponential Enrichment (SELEX) screens aptamer-only libraries and conjugates them to delivery vehicles after selection, we hypothesized that specific delivery requires screening libraries with aptamer-nanoparticle conjugates. We designed a procedure called, "Conjugate-SELEX", where liposomal nanoparticles (LNP) conjugated with aptamers is screened to identify aptamers that carried attached LNPs to the human head and neck squamous cell carcinoma cell cytosol. Aptamer-LNPs were simultaneously selected for a low affinity to human hepatocytes, minimizing hepatoxicity and LNP clearance. Post-SELEX Next Generation sequencing demonstrated convergence to a family of sequences with one base difference. Affinity pulldown and proteomics analysis identified the uptake-mediating surface receptor as the neuroblast differentiation-associated protein AHNAK (Desmoyokin), a ubiquitous intracellular protein expressed in certain epithelial cell types. Uptake studies with the lead aptamer-conjugates showed enhanced uptake and increased cytotoxicity induced by doxorubicin in cells treated with aptamerconjugated LNPs over LNP controls. Conjugate-SELEX identifies aptamers capable of targeted cytosolic delivery of attached LNPs payload, while minimizing off-target delivery. The technique lends itself to identification of uptake-mediating surface receptors.
Introduction
Developing nanoparticles, capable of targeting and delivering diverse payloads of drugs and imaging probes to solid malignancies remains a critical challenge to cancer nanomedicine. 1, 2 Previous studies have successfully used targeting ligands ranging from small molecules (e.g., Folate) to antibodies for this purpose, but these ligands have limited utility due to intra and intertumoral heterogeneity. 2 Aptamers are emerging as attractive alternatives for antibodies and small molecule drugs in several clinical applications. Aptamers are short, single-stranded oligonucleotides that can fold into unique tertiary structures and bind to their target molecules with high specificities and affinities, much like antibodies. However, unlike antibodies, aptamers are nonimmunogenic and can be bulk-synthesized with ease, and at a low-cost without batch-to-batch variations. [3] [4] [5] [6] Since native oligonucleotides are vulnerable to degradation by cellular nucleases, chemical modifications are required to make oligonucleotides more resistant to digestion by nucleases. Substituting one or both of the nonbridging oxygens with sulfur not only increases the chemical stability of the oligonucleotides, but also has been shown to increase their binding affinities toward protein targets. 6 Thioaptamers (TA) with monothiophosphate modified backbones are more resistant to nuclease digestion and have higher affinities to their targets than unmodified aptamers. 6 Aptamer libraries, consisting of ~10 14 unique sequences, are far larger than typical small molecule compound libraries, therefore increasing the probability of finding hits for tumor-specific targets.
Systematic Evolution of Ligands by Exponential enrichment (SELEX) 7, 8 enables multiplex multistage aptamer screening, with specific candidate amplification at each stage, thus rapidly narrowing the enormous library to a small number of aptamers with high-target affinity. SELEX can be modified to use live cells as the selection target (cell-SELEX), thus selecting aptamers that bind specific cellular components in their native conformation. [9] [10] [11] All of these studies have screened aptamers as free molecules, under the assumption that aptamer behavior remains unchanged when a payload is attached. 12 Cell-SELEX isolates aptamers based on their binding to the target protein on the cell surface, but it is not capable of generating aptamers that internalize in cells for cytosolic drug delivery. 13 We hypothesized that screening a library of Aptamer-liposomal nanoparticle (Aptamer-LNP) conjugates would identify aptamers that enable internalization of LNPs and their payload. Therefore, we developed a screening process, called "Conjugate-SELEX", depicted in Figure 1 . In this process, the aptamer library is conjugated to LNPs, under stoichiometric conditions that place a small number of TAs on each particle (~10 TAs per LNP). Then, unlike other SELEX processes, where aptamers are screened as free molecules, the TA-LNP library itself is screened at each cycle of Conjugate-SELEX. At each cycle, TAs recovered from the desired cellular compartment (in this case, the cytosol) are amplified, and used to create the conjugate sublibrary for the next cycle of Conjugate-SELEX. Negative screens against off-target cells are incorporated into the process, facilitating the identification of a TA that efficiently transports payload into target cells while minimizing the uptake in off-target cells. Using fluorescently labelled LNPs, imaging the cells at each cycle verifies the successful transport of the LNP payload into the cytosol.
This study sought to isolate internalizing TA-tagged LNP (TA-LNP) using head and neck squamous cell carcinoma (HNSCC) cells as the target. Globally, HNSCC is the sixth most common cancer. Current treatment with surgery or chemoradiation is associated with high mortality (<50% 5-year survival). 14 An important reason for the high mortality rate of HNSCC is >60% of the patients with HNSCC having an advanced disease (stage III or IV) at the time of diagnosis. This group of patients has poor prognosis because of loco-regional and/or distant metastasis that is fundamentally incurable with currently available treatments. Current chemoradiation therapies cause significant collateral toxicity to the normal organs and tissues and therefore fail to reduce morbidity and mortality. Developing a strategy to selectively deliver anticancer drugs to tumors, while sparing healthy tissue from dose-limiting, side effects are worthy goals. Targeted delivery of anticancer drugs via LNPs alters drug pharmacokinetics and could improve efficacy and reduce toxicity. PEGylated LNP drugs have been evaluated for drug delivery in patients with locally advanced solid cancer and among these tumors, HNSCC showed the highest uptake of LNPs. 15 For successful delivery of conventional chemotherapy agents and siRNA, LNP carriers should enter tumor cells and release their payload into the cytosol or, if possible, to the actual site of drug action. However, entrapment and degradation of siRNA or other payloads in endolysosomes prevent such intracellular delivery of the functional drug. 16, 17 The use of tumor penetrating peptides has been shown to facilitate cytosolic delivery of siRNA nano complexes by endosomal escape. 18 This study successfully used a screening methodology for isolating tumor penetrating peptides that promoted cytosolic delivery of siRNA complexed by a myristoyl nanoparticle. 18 In an analogous manner, we used Conjugate-SELEX to isolate TAs that are capable of delivering the attached LNP payload to the cytosol of HNSCC cells, while not being taken up by immortalized hepatocytes. The resulting TAs was shown to enhance uptake into HNSCC cells and deliver their payload efficaciously.
Results

Selection of internalizing TA-LNP library
The Conjugate-SELEX process was monitored with polymerase chain reaction (PCR), gel-electrophoresis and fluorescence image cytometry to confirm the cytosolic uptake of TA-LNP in UM-SCC-22A cells (see Supplementary Figures S1, S2, and S3). The normal primary human hepatocyte cell line (THLE-3) was used in the negative selection, cycles #13 and #14. Supplementary Figure S1 shows the gel electrophoresis images of the amplified PCR products of Conjugate-SELEX cycles #8 (A), #14 (B; negative selection) and #15 (C). Cytosolic fractions of untreated cells, cells treated with free LNPs on cells and a mock PCR reaction without template were used as appropriate controls to confirm the specificity of the PCR reactions while excluding any potential contamination. Amplified products of the internalized (cytosolic fraction; lane #6) TA-LNP fraction is clearly evident after cycle #8 with a substantial proportion of TA-LNP fraction remaining from noninternalized fraction (supernatant; lane #5), indicating that the Conjugate-SELEX had not fully eliminated all noninternalizing TA-LNPs. Subsequent negative selection at cycle #14 with the THLE-3 cells (B) revealed that a small fraction of internalizing TA-LNPs were also taken up by hepatocytes as evidenced by amplified PCR product in lane#7. Selecting the noninternalized fraction from the supernatant from the negative selection (lane# 5) ensured that only the TA-LNP fraction not taken-up by hepatocytes was selected for subsequent Conjugate-SELEX cycles. The gel electrophoresis from cycle #15 (C) revealed a bright and sharp band (lane #6) representing the amplified product of the cytosolic fraction of internalized TA-LNPs confirming the enrichment of the internalized TA-LNPs by UM-SCC-22A cells.
The enrichment of cytosolic TA-LNPs with each cycle of Conjugate-SELEX was simultaneously monitored by image cytometry, beginning at cycle #5(see Supplementary Figure S2 ). TA-LNPs with Cyanine dye-3 (Cy3)-labeled TA and 7-nitrobenzo-2-oxa-1,3-diazole (NBD)-labeled LNPs were imaged, and images were analyzed for label colocalization in the Figure S3 ). The average per-cell LNP:TA ratio (based on pixel intensity in arbitrary units of fluorescein isothiocyanate (FITC):TRITC channels) for each cycle was then plotted in order to determine the efficacy of the TA in delivering the LNP to the cytosol of UM-SCC-22A cells (see Supplementary Figure S2 ). In Supplementary Figure S2 , the NBD staining (LNP) appears more intense than the Cy3 (TA), due to the fact that there are several thousand NBD molecules encapsulated in an LNP while there is only one Cy3 per TA, and ~10 TA molecules in each LNP. Supplementary Figure S3 shows the ratio of intensity in the FITC channel (an indicator of total LNP) to that of the TRITC channel (an indicator of the number of TA) plotted against Conjugate-SELEX cycle number. The increasing trend (positive slope) indicates improving TA efficiency in facilitating LNP delivery as Conjugate-SELEX proceeds.
These results were also consistent with DNA sequencing results, identifying the top 250 most commonly occurring sequences from the nearly two million unique sequences present on the Next Generation sequencing chip. Significant amplification of these sequences is evident after cycle #6 of Conjugate-SELEX. The abundance of these sequences increased with additional selection cycles (Figure 2a ). Some of these sequences were missing after the two negative selection cycles, while the relative abundance of a few sequences increased steadily with Conjugate-SELEX cycles (Figure 2a ). The negative selections had a profound effect in revealing target affinity of certain sequences. The abundance of TA seq#1 increased 360-fold from cycle #7 to cycle #15 including the negative selection cycles #13 and #14 (Figure 2a) . In contrast, the abundance of some of the TA sequences decreased after the negative selection cycles (Figure 2a) . Supplementary Table S1 lists the top 14 most frequently occurring TA sequences after 15 rounds of Conjugate-SELEX selection cycles. These sequences were clustered into two unique families based on the similarities of their primary sequences (Figure 2b) . The TA-seq#5, seq#3, seq#12, and seq#14 form a cluster while the other 10 sequences form the second cluster. Notably, the latter cluster of 10 sequences only exhibits a one base difference from each other, suggesting an extremely close relationship among the converged TA sequences (Figure 2b ; Supplementary Table S1 ). This convergence in selection demonstrates that the Conjugate-SELEX successfully narrowed an extremely large library down to a significantly smaller pool of TA-LNP conjugates suitable for further characterization. Among the top 10 enriched TA sequences, seq#1(TA-seq#1) showed the highest selectivity for internalizing into UM-SCC-22A cells with simultaneous exclusion from hepatocytes and was therefore selected for subsequent functional studies. Supplementary Table S1 . Note the existence of three clear families. The main family (Seq #1, Seq #2, Seq #4, Seq #14, Seq #16, Seq #17, and Seq #19) only differ by one base. The second family (Seq #7, Seq #7, and Seq #8) differ only by one base between themselves, and by about 5 bases from family 1. The third family (Seq #3, Seq #5, Seq #11, and Seq #14) is fairly loose; differing by about 6-7 bases between the members, and is completely distinct from families 1 and 2, differing by about 25 bases out of a total of 30. (c) Seq #1 mfold structure. SELEX, Systematic Evolution of Ligands by Exponential Enrichment. The target protein of TA-seq#1 was identified using proteomic analysis by affinity-immuno-pull down followed by massspectrometry. The identified proteins were ranked according to their abundance scores. Based on the high abundance (high average total ion current value) and high specificity, AHNAK was selected as a potential target for TA-seq#1. AHNAK was present only in the samples binding to TA-seq#1 but not in the sample with the control sequence, R4 (see Supplementary Table S2 ). AHNAK, also known as Desmoyokin, is an exceptionally large protein (700 kDa) consisting of three main structural regions-NH 2 -terminal, a large central region with repetitive elements, and the COOH-terminal. 19 UM-SCC-22A cells expressed high levels of AHNAK both at the cell surface and intracellularly when examined using immunofluorescence and immunohistochemical staining (Figure 3 and Supplementary Figure S4) . In UM-SCC-22A cells, AHNAK was preferentially localized to the cell surface in a confluent culture with cell-to-cell contacts. Moreover, expression of AHNAK is also noted within the pseudopodia of these cells (see Supplementary Figure S4 ). We examined a panel of cell lines derived from HNSCC and carcinomas of other organs and found that AHNAK is expressed at high levels in most of these epithelial derived malignancies in accordance with previous published reports. 20 In addition, we examined three cell lines with different levels of AHNAK expression (see Supplementary Figure S5 ). Among the cell lines tested only the ovarian cancer cell line MOSEC showed low AHNAK expression.
Cellular uptake of LNP conjugated TA-seq#1 (TA-LNP-#1)
First, we examined whether blocking AHNAK expression in UM-SCC-22A cells using either AHNAK-siRNA or antibody reduces the uptake of TA-LNP-#1. We used a synthetic siRNA to silence the AHNAK and examined the uptake of fluorescently-labelled TA-LNP-#1. We were unable to achieve a complete knock-down of AHNAK protein expression in the UM-SCC-22A cells using the siRNA. Partial siRNA -mediated inhibition of AHNAK protein in UM-SCC-22A cells did not significantly impact the uptake of TA-LNP-#1 compared with mock-transfected cells (data not shown), possibly due to membrane AHNAK remaining, while intracellular AHNAK was preferentially silenced. Similarly, antibody mediated blocking of AHNAK in UM-SCC-22A cells did not significantly reduce the uptake of TA-LNP-#1 when compared with control cells, potentially because the selected TA and the antibody bind to different epitopes in the protein. Next, we tested the difference in the uptake of TA-LNP-#1 between cell lines with high (UM-SCC-22A) and low (MOSEC) AHNAK expression. The TA-LNP-#1 showed from 2.5-fold to fourfold higher uptake level in UM-SCC-22A cells compared with MOSEC cells, while the uptake of R4-LNP (control) was not significantly different between these two cell lines (Figures 4 and 5) . Furthermore, in cellular uptake studies, the TA-LNP-#1 showed preferential uptake by UM-SCC-22A cells compared with the normal hepatocytes (THLE-3) (see Supplementary Figure S6 ).
Cytotoxic effect of doxorubicin delivered by TA-LNP-#1 in UM-SCC-22A cells
PEGylated (Doxil; Caelyx) and non-PEGylated (Myocet; LipoDox) liposomal doxorubicin have been tested in clinical trials and approved for treating various types of solid epithelial malignancies including recurrent HNSCC. 21, 22 Doxorubicin, a topoisomerase II inhibitor, requires intracellular delivery as a prerequisite to activity. Previous studies have demonstrated the cytotoxic effect of doxorubicin against HNSCC cells including UM-SCC-22A cells. 23, 24 Therefore, we tested the cytotoxic effect of doxorubicin loaded TA-LNP-#1 against UM-SCC-22A cells and compared it with the same by the untargeted (PEGylated)-LNP loaded with doxorubicin. The IC 50 values of targeted (TA-LNP-#1) and nontargeted (PEGylated-LNP) Doxorubicinloaded LNPs against UM-SCC-22A cells were calculated at 48 and 72 hours of exposure (Figure 6) . The IC 50 values for doxorubicin loaded TA-LNP-#1 were consistently lower than those for nontargeted LNPs with doxorubicin ( Figure 6 ) suggesting that the TA-LNP-#1 enhances intracellular functional delivery of doxorubicin to the target cells with greater efficiency than the nontargeted-LNP in a dose-response manner (see Supplementary Figure S7 ). Increased cytotoxicity induced by doxorubicin delivered via TA-LNP-#1 confirms the cytosolic delivery of the drug in targeted cells. In addition, it demonstrated stronger dose-response manner in TA-LNP-#1 than R4-LNP in Supplementary Figure S7 . 
Discussion
Nanoparticles can be used to enhance the bioavailability of drugs to target cells while minimizing nonspecific distribution to off-target, normal tissue. Among the diverse groups of nanoparticles being investigated for drug delivery, LNPs show great potential as drug carriers and are currently in use as a drug delivery system for cancer treatment. 21 We opted to use LNP over other nonviral drug carriers for this study because their toxicity and immune stimulation are well understood 25 and ligands can be easily conjugated to the LNP surface for active targeting. Anticancer drugs delivered using LNP extravasate more rapidly into tumors with "leaky" neovasculature than in normal tissue. This enhanced permeability and retention of LNP encapsulated drug complexes in tumors increases their therapeutic efficacy while reducing their toxicity. In a previous report, we isolated a TA against E-selectin (ESTA-1) and conjugated LNP to target vascular endothelial cells in vitro and breast cancer xenografts. 12, 26 However, cytosolic delivery of siRNA using LNP faces several important barriers including rapid hepatic clearance and the lack of specific tumor-cell-targeting. In addition, entrapment and degradation of LNP-siRNA complexes in endolysosomes prevents the release of functional siRNA into the cytoplasm. 16, 17 Moreover, adverse effects of drugs and diagnostic imaging agents delivered by LNP in patients are attributed to the lack of targeting specificity and liver toxicity. To circumvent these obstacles, we designed a novel strategy "Conjugate-SELEX" to efficiently isolate LNP-conjugated DNA aptamers for targeted delivery of anticancer drugs to the cytosol of tumor cells. Traditionally cell-SELEX is used to isolate highaffinity binding aptamers from a large library of random oligonucleotides against membrane proteins of a whole cell in their native conformation. 27 However, it is difficult to predict whether the isolated aptamers using cell-SELEX are capable of delivering the conjugated payload to the cytosol of the target cells. Unlike cell-SELEX, Conjugate-SELEX enables the isolation of aptamer conjugated LNP that efficiently enter into the cytosol of targeted tumor cells. In order to eliminate hepatocyte internalized TA-LNPs that could cause liver toxicity, we performed negative selection cycles against immortalized hepatocytes.
Next generation sequencing demonstrated enrichment of specific aptamers visible from about cycle #10, and confirmed that Conjugate-SELEX enriches aptamers with the highest affinity for internalizing into the target cells. Analysis of the sequencing data from each stage of Conjugate-SELEX showed the systematic enrichment of certain sequences. The negative selection cycles eliminated some of these hits, and continued positive selection cycles led to the identification of 14 TA sequences that were preferentially enriched with increasing Conjugate-SELEX cycles. These top 14 sequences fell into two families, exemplified by TA-seq-#1 and TA-seq-#5, which had the highest occurrences and unique structures. These two families differ by about 5 bases while entries within each family differ by only one base. They were further characterized in uptake experiments using image-based cytometry, and shown to have high abilities to localize attached liposomal payload within the target HNSCC cells. We selected the most prevalent hit sequence TA-seq-#1 for target identification and characterization. We used affinity pull-down followed by mass spectrometry and identified AHNAK as the likely cell surface target for TA-seq-#1 binding and entry into the cells. AHNAK is a large protein with an approximate molecular weight of 700 kDa. 20 Initial studies reported AHNAK as a nuclear protein expressed in neuroblastoma cells. 19 Recent findings indicate that AHNAK is a ubiquitous protein expressed in a variety of cell types and this protein shuttles between nucleus, cytoplasm, and cell membrane depending on the cell type and the activation/ transformation status. 20 AHNAK localization in squamous epithelial cells varies depending on the formation of cellto-cell contacts, extracellular calcium concentration and its phosphorylation status. 20 Our immuno-histochemical studies suggest that AHNAK is expressed in high-levels in UM-SCC-22A cells and it is localized predominantly within the nucleus and cytoplasm of the tumor cells that lacking cell-to-cell contact, whereas it is expressed on the cell surface of tumor cells that have cell-to-cell-contact. Moreover, UM-SCC-22A cells express AHNAK in their pseudopodia protrusions which form the invadopodia necessary for the tumor cell migration and invasion. 20 We also examined the expression of AHNAK in tumor cells derived from human and murine carcinomas of different organs including HNSCC and found that most of these tumor cells express high to moderate levels of AHNAK and found the lowest level expression in murine ovarian cancer cell line MOSEC. Previous studies have also reported that expression levels of AHNAK are upregulated in carcinomas and mesotheliomas compared with their parental normal cells. 20 AHNAK is expressed in low levels in healthy squamous epithelial cells while it is frequently overexpressed in HNSCC. Its overexpression is significantly associated with poor survival of this patients. 28 The presence of high-levels of AHNAK in UM-SCC-22A cells made it difficult to completely silence its expression using RNAi to evaluate its effect on the uptake of TA-LNP-#1. Similarly, antibody-based blocking of AHNAK in UM-SCC-22A cells did not cause any significant difference in the uptake of TA-LNP-#1. There are two possibilities for the inability of the AHNAK antibody to block the TA-LNP-#1from entering into the tumor cells. One being that the AHNAK antibody and TAseq-#1 bind to two distinct epitopes. Alternatively, antibody binding was not effective in blocking all the TA-seq-#1 binding epitopes due to the abundance of AHNAK expression in UM-SCC-22A cells. However, the uptake of TA-LNP-#1 uptake was significantly lower in MOSEC cells with low, mostly cytoplasmic AHNAK expression compared with UM-SCC-22A cells suggesting that cell surface expression of AHNAK plays a role in the uptake of TA-LNP-#1. Additionally, doxorubicin delivered using TA-LNP-#1achieved more effective killing of UM-SCC-22A cells with significantly lower IC 50 value compared with doxorubicin delivered using untargeted LNP.
Increased expression of AHNAK in metastatic variants of lung carcinoma cells is mediated by the transforming growth factor-β induced epithelial to mesenchymal transition. 20 This data suggests increased expression of AHNAK may promote tumor progression and metastasis. Shuttling of AHNAK between cell surface and cytoplasm may have a role in delivering the bound TA LNP-#1 to the cytoplasm of the targeted cells. Hence, AHNAK represents a unique molecule for aptamer targeted cytosolic delivery of anticancer drugs. Although we have focused on TA -LNP-#1 delivery platform to target HNSCC cells, this drug delivery platform can be used for other carcinomas with high AHNAK expression levels. Cell surface localization of AHNAK which lacks the transmembrane domain necessary for cell surface expression is facilitated by forming a multimeric complex with actin and the Annexin 2/S100A10 complex. 20 It is interesting to note the Annexin and S100A proteins have been identified as target proteins for aptamers selected using cell-SELEX. 27 It is tempting to speculate that perhaps the structural conformation of the AHNAK-Annexin-S100A10 complex favors aptamer binding in its native state.
In summary, we report here on Conjugate-SELEX, a novel method of identifying vehicles for targeted drug delivery used to find the first well-characterized TA that specifically binds to and enters the HNSCC cells with its conjugated payload. We showed that this TA is capable of delivering the LNP to the cytosol as measured by both image cytometry and doxorubicin cell-killing assay. Although we have used liposomes in this study, other nanoparticles can also be used for Conjugate-SELEX, e.g., multi-functional RNA nanoparticles have been successfully used for delivery of siRNA and anti-miRNA molecules for cancer cells. 29 We identified AHNAK as a potential target of the TA-seq#1; moreover, AHNAK is overexpressed and localized on the cell surface of HNSCC cells. This selection process is designed to select TA-LNP conjugates that will likely have the highest therapeutic index by virtue of maximum uptake into tumor cells and a simultaneous, minimal uptake into off-target cells.
Materials and methods
Cell lines and reagents. UM-SCC-22A cell line, derived from a primary oropharyngeal squamous cell carcinoma was obtained from Thomas E. Carey (Department of Synthesis of primers and TA DNA library. All reagents required for the oligonucleotide synthesis were purchased from Glen Research (Sterling, VA), except the dATP (αS) which was obtained from Axxora Life Sciences (San Diego, CA). The single-stranded DNA TA library consists of a 30-mer random region flanked by PCR primer regions to enable the PCR amplification of the sequence (5′-GATATGTCTAGAGCCT-CAGATCA-(N) 30 -CGGAGTTATGTTAGCAGTAGC-3′). The initial template was chemically synthesized using standard phosphoramidite chemistry 31 and the library was created by PCR amplification of the template. During the PCR, dATP (αS) was used, resulting in the DNA sequences where the 3′ phosphate of each A residue is substituted with monothiophosphate groups, as described in detail, previously. 3, 4, 32 One of the primers was synthesized with the Biotin and the other with the Cy3 fluorophore and carboxyl groups at their 5′ ends. After PCR amplification, the biotin labeled strands were isolated using streptavidin beads and were removed from the PCR products, leaving the Cy3 and carboxy labeled strands for conjugation to the liposomes for Conjugate-SELEX cycles. The concentration of the TA library was determined by measuring the UV absorbance at 260 nm. Preparation of TA-LNP conjugates. Carboxy-Cy3 labeled single stranded DNA molecules were conjugated to amino-PEG liposomes using carbodiimide chemistry with 1-Ethyl-3-(3dimethylaminopropyl) carbodiimide (EDC) and sulfo-N-Hydroxysuccinimide (NHS). 33 Dialysis through a 100 kDa membrane was used to remove free DNA and small molecule byproducts of EDC and sulfo-NHS reactions. The final concentration of TA-LNP was quantified by measuring Cy3 fluorescence.
Conjugate-SELEX. The TA-LNP conjugates were incubated at 37°C for 2 hours with UM-SCC-22A cells for positive selections or with THLE-3 human hepatocytes for negative selections. Following the incubation, for positive selections, the cells were treated with trypsin to remove any TA-LNPs bound to the membrane proteins, mechanically lysed, and centrifuged. The cell pellet was suspended with fractionation buffer (10 mmol/l tris (hydroxymethyl) aminomethane/acetic acid, pH 7.0, 250 mmol/l sucrose) and homogenized. The cell homogenate was centrifuged at 2,000×g and 4,000×g to isolate pellet debris and/or undestroyed cells, plasma membrane and/or nuclei, respectively. The cytosolic fraction was then separated by ultracentrifugation at 400,000×g. DNA in the cytosol was purified using the QIAamp DNA Blood Mini Kit (Qiagen). The cytosolic fraction was PCR-amplified to monitor the presence of internalized TAs at each cycle. For negative selections, the supernatant was simply pipetted out of the flask and processed for the next round of selection. The TAs in the desired compartment (cytosol for positive selections, unbound supernatant for negative selections) were amplified by PCR, and used to prepare the TA-LNP conjugates for the next round of selection. A total of 15 cycles of Conjugate-SELEX were conducted, including two negative selections at cycles #13 and #14.
Image-based cytometry. We used image-based cytometry to evaluate the progress of the Conjugate-SELEX, by measuring the intracellular uptake of TA-LNP pools in the target cells starting from the cycle #5 and continued through cycle#15. Cy3 labelled-TA-LNP conjugate library loaded with green fluorescent dye NBD) was used to evaluate the intracellular uptake in UM-SCC-22A cells. Cells grown in microscopic chamber slides were incubated with the fluorescently-labelled TA-LNP conjugates libraries of different selection cycles for 2 hours. Treated and control cells were washed in PBS, fixed with 4% formaldehyde, counterstained with DAPI and imaged using a Nikon Eclipse TE2000E wide-field fluorescence microscope (Nikon Instruments, Melville, NY). These fluorescent images were analyzed using the colocalization algorithm within Cyte-Seer Software version 2.6 (Vala Sciences, San Diego, CA).
In addition, we evaluated the intracellular uptakes of the TA-LNP-#1and R4-LNP (control) in Conjugate-SELEX between a normal hepatocyte cell line, THLE-3 and compared it with their respective uptake in Conjugate-SELEX targeted cell line UM-SCC-22A cells, derived from a primary oropharyngeal squamous cell carcinoma by confocal imaging. Cy3-labelled-TA -LNP conjugate library loaded with green fluorescent dye, NBD, was used to visualize and estimate the uptake in both cell types. Cells grown in microscopic chamber slides were incubated with the fluorescently-labelled TA-LNP-#1 and R4-LNP conjugates for 2 hours. Treated and control cells were washed in PBS, fixed with 4% formaldehyde, counterstained with DAPI and imaged using a Nikon Eclipse Ti confocal microscope (Nikon Instruments, Melville, NY).
Sequencing of TA libraries. At each cycle after the seventh cycle of Conjugate-SELEX, the cytosolic fractions were isolated and the recovered TA sequences were amplified by PCR. Equimolar quantities of the recovered TA sequences from cycles #7 to #15 were pooled together and sequenced by Next-Gen DNA sequencing using Ion318 chip (ThermoFisher, Waltham, MA). A four base sequence was introduced during PCR amplification to serve as unique "barcode" to distinguish between Conjugate-SELEX cycles. Sequencing results were analyzed by the Aptalinger program 34 that uses the Markov model probability theory to find the optimal alignment of the sequences.
Doxorubicin cytotoxicity studies. TA-seq-#1 was selected as the lead TA candidate based on the sequencing data and was conjugated to LNPs loaded with doxorubicin (see Supplementary Table S1 ). UM-SCC-22A cells were treated with the Doxorubicin carrying TA-LNP-#1 and cytotoxicity was evaluated via MTT assay at 48 and 72 hours at varying concentrations of Doxorubicin. A control group consisting of untargeted, doxorubicin-encapsulating liposomes (recapitulating the clinically used Doxil) was also tested. Incubation was conducted in fetal bovine serum to replicate blood serum proteins. The IC 50 values for both the targeted and untargeted formulations were calculated.
Characterization TA-LNP-#1 target in UM-SCC-22A cells. The protein target(s) of TA-seq-#1, were identified by affinity-pull down using TA-seq-#1 as the capturing reagent followed by mass-spectroscopy. A scrambled DNA sequence, R4, was used as a control. The UM-SCC-22A cells, at 90-95% confluence were washed with cold PBS buffer and were incubated with biotinylated TA-seq-#1 and R4 (24 mmol/l each) individually at 4°C, in PBS (Dulbecco's PBS with calcium chloride (0.901 mmol/l) and magnesium chloride, Life Technologies) with gentle agitation for 2 hours. After incubation, UM-SCC-22A cells were cross-linked with 1% formaldehyde for 10 minutes at room temperature. The formaldehyde cross-linking was quenched with glycine. Cells were scraped from the flask, washed and lysed with buffer (lysing buffer, Pierce Biotechnology) and treated with protease inhibitor mixture (Sigma). The lysates were freeze-thawed for 30 minutes on ice and cleared by centrifuging at 10,000×g for 2 minutes at 4°C. To pull down the cross-linked proteins, equal amounts of cell lysate were incubated with prewashed streptavidin magnetic beads for 1 hour at room temperature with continuous rotation. Protein digestions were performed on the beads to isolate targeted protein(s) and processed for mass spectrometric analysis. Each sample was analyzed in triplicates. The raw data files were processed to generate a Mascot Generic Format with Mascot Distiller and searched against the SwissProt_2012_01 (Human) database using the licensed Mascot search engine v2.3.02 (Matrix Science) run on an in-house server.
Validation of AHNAK as target for TA-LNP-#1 in UM-SCC-22A cells Immunostaining for AHNAK. Immunofluorescence and immunohistochemical staining were performed to determine the expression levels and cellular localization of AHNAK protein in UM-SCC-22A and MOSEC cells. Cells grown to >75% confluence were fixed in microscopic chamber slides were fixed in 2% paraformaldehyde and used for immunostaining using a polyclonal antibody against AHNAK protein. For immunohistochemistry, staining with anti-AHNAK antibody was performed using VECTASTAIN Elite ABC -Rabbit IgG kit (Vector Laboratories, Burlingame, CA) as per manufacturer's instructions and 3, 3′-Diaminobenzidine was used as chromogenic substrate. Cells were counterstained with hematoxylin, dehydrated and mounted. For immunofluorescence staining, cells were incubated with anti-AHNAK antibody (1:100) followed by biotinylated-goat-anti-rabbit antibody (1:500, DAKO) and Streptavidin Alexa Flour 448 conjugate (1:200; Thermo-Fisher). Cells were counterstained and mounted using the ProLong Gold Antifade Mountant with DAPI (ThermoFisher) and imaged using a Nikon fluorescent microscope. siRNA mediated inhibition of AHNAK in UM-SCC-22A. Human AHNAK siRNA (sc-97060) was obtained from Santa Cruz Biotechnology (Dallas, TX) and reconstituted according to the manufacturer's instructions. UM-SCC-22A cells were grown to semiconfluence and used for siRNA transfection using the Nucleofector system (Amaxa Biosystems Cologne, Germany). Tumor cells (1.0 × 10 6 ) were resuspended in 100 μl Cell Line Nucleofector Solution L and mixed with 1 μg of AHNAK siRNA and controlled scrambled siRNA. To evaluate transfection efficiency, the same numbers of cells were transfected with pMax-GFP plasmid encoding green fluorescent protein. Nucleofection was done using the Amaxa Nucleofector device with the V33 program. Cells transfected with siRNA and mock transfected cells were plated in microscopic chamber slides used for imagebased cytometry of TA-LNP-#1 uptake as described above.
Blocking of cell surface AHNAK in UM-SCC-22A cells with an antibody. The AHNAK antibody blocking was performed in UM-SCC-22A cells to determine their specificity to TA-LNP-#1. Tumor cells were grown overnight in microscopic chamber slides to semiconfluence. Next day, cells were washed with PBS, incubated with 5% bovine serum albumin (BSA) in PBS for 45 minutes before treating with the polyclonal rabbit antihuman AHNAK antibody (4 μg/ml in 1% BSA-PBS) for 1 hour. Subsequently cells were washed with PBS-T (0.01% Tween-20 in PBS) three times and treated with 15 μl of the fluorescently-labelled TA-LNP conjugate with appropriate controls in reduced serum media (Opti-MEM, Mediatech, Manassas, VA) for 2 hours. Treated and control cells were subjected to imagebased cytometric analysis as described above. Figure S1 . Gel electrophoresis of Conjugate-SELEX. Figure S2 . Epifluorescent images of UM-SCC-22A cells after two hours of incubation with TA-LNP conjugates. Figure S3 . Uptake efficiency of TA-LNP's into UM-SCC-22A cells after two hours of incubation. Figure S4 . Representative immunohistochemical staining images demonstrate the cell-contact induced differential localization of AHNAK in UM-SCC-22A cells. Figure S5 . AHNAK levels in UM-SCC-22A, MOSEC and SKOV3cancer cells. Figure S7 . MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium Bromide) assay was to evaluate doxorubicin dose-dependence cytotoxicity on UM-SCC-22A cells. Table S1 . The most frequently occurring sequences in order of abundance were identified by Ion Torrent Next Generation of Sequencing .  Table S2 . Proteomics results by Mass Spectrometry to demonstrate AHNAK was present only in the samples specific binding to TA-seq-#1 but not in the sample with the control R4.
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